Assessment of Predictors of Hyperkalemia in Cardiovascular Diseased Patients
Abstract
Purpose: The objective is to determine the predictors of hyperkalaemia, severity of hyperkalaemia and to access the prevalence of cardiovascular diseases
Methodology: A cross sectional observational study was conducted on the predictors of hyperkalaemia in CVD patients, in a tertiary care teaching hospital for a period of 6 months.
Results: Among 105 patients, there were 83 males and 22 females, the age group from 41-60 year shows more CVDs and 61-80 years aged patients are more prone to hyperkalaemia and shows more prevalent when compared to other age groups. The major risk factors of hyperkalaemia were Drugs (30.23%), Disease (58.13%), and Drug interactions (11.62%).Among the cardiovascular diseases, Myocardial Infarction (38%) were the most common type of CVD, while in hyperkalaemia Ischemic Heart Disease (48.83%) were more prevalent. The severity of hyperkalaemia is measured as Mild (60.46%), Moderate (37.20%), and Severe (2.32%).
Conclusion: The present study was carried out in order to assess the predictors, prevalence and severity of hyperkalaemia in cardiovascular disease patients. Our study concluded that patients with cardiovascular disease can have an increased risk of hyperkalaemia.
Keywords: CVD, Hyperkalaemia, Cross sectional observational study, Predictors, Prevalence, Severity.
Keywords:
CVD, Hyperkalaemia, Cross sectional observational study, Predictors, Prevalence, SeverityDOI
https://doi.org/10.22270/jddt.v11i2.4587References
Aiswarya A T, et al. A Study on the Assessment of Risk Factors and Evaluation of Prescribing Pattern in Patients with Hyperkalemia Having Cardiovascular Disorders”, International journal of pharmacy and pharmaceutical research,vol 2018; 11(4)
Núñez Julio et al. "Long-Term Potassium Monitoring And Dynamics In Heart Failure And Risk Of Mortality". Circulation, 2018; 137(13):1320-1330. Ovid Technologies (Wolters Kluwer Health), doi:10.1161/circulationaha.117.030576.
High potassium (hyperkalemia) [Internet] 2018 Jan 11. Available form: https://www.mayoclinic.org/symptoms/hyperkalemia/basics/definition/sym-20050776
Alldredge B, Koda-Kimble M, Young L. Applied therapeutics. Philadelphia, Pa.: Wolters Kluwer / Lippincott Williams & Wilkins; 2013
Michel Alexander et al. "Risk Factors For Hyperkalaemia In A Cohort Of Patients With Newly Diagnosed Heart Failure: A Nested Case-Control Study In UK General Practice". European Journal Of -9-Heart Failure, 2015; 17(2):205-213. Wiley, doi:10.1002/ejhf.226.
Alderman Michael H. et al. "Clinical Significance Of Incident Hypokalemia And Hyperkalemia In Treated Hypertensive Patients In The Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial". Hypertension, 2012; 59(5):926-933. Ovid Technologies (Wolters Kluwer Health), doi:10.1161/hypertensionaha.111.180554.
Ahee P. "The Management Of Hyperkalaemia In The Emergency Department". Emergency Medicine Journal, 2000; 17(3):188-191. BMJ, doi:10.1136/emj.17.3.188.
Martín-Pérez Mar et al. "Impact Of Hyperkalaemia Definition On Incidence Assessment: Implications For Epidemiological Research Based On A Large Cohort Study In Newly Diagnosed Heart Failure Patients In Primary Care". BMC Family Practice, 2016; 17(1). Springer Science And Business Media LLC, doi: 10.1186/s12875-016-0448-5.
Amir Omalhassan et al. "Incidence Of Risk Factors For Developing Hyperkalemia When Using ACE Inhibitors In Cardiovascular Diseases". Pharmacy World & Science, 2009; 31(3):387-393. Springer Science And Business Media LLC, doi:10.1007/s11096-009-9288-x.
Vardeny, Orly et al. "Incidence, Predictors, And Outcomes Related To Hypo- And Hyperkalemia In Patients With Severe Heart Failure Treated With A Mineralocorticoid Receptor Antagonist". Circulation: Heart Failure, 2014; 7(4):573-579. Ovid Technologies (Wolters Kluwer Health), doi:10.1161/circheartfailure.114.001104.
de Denus, Simon et al. "Quantification of the Risk and Predictors of Hyperkalemia in Patients with Left Ventricular Dysfunction". American Heart Journal, 2006; 152(4):705-712. Elsevier BV, doi:10.1016/j.ahj.2006.05.030.
Desai, Akshay S. et al. "Incidence And Predictors Of Hyperkalemia In Patients With Heart Failure". Journal Of The American College Of Cardiology, 2007; 50(20):959-1966. Elsevier BV, doi:10.1016/j.jacc.2007.07.067.
Acker, Christopher G. et al. "Hyperkalemia In Hospitalized Patients". Archives Of Internal Medicine, 1998; 158(8):917. American Medical Association (AMA), doi:10.1001/archinte.158.8.917.
Jain, Nishank et al. "Predictors Of Hyperkalemia And Death In Patients With Cardiac And Renal Disease". The American Journal Of Cardiology, 2012; 109(10):1510-1513. Elsevier BV, doi:10.1016/j.amjcard.2012.01.367.
Khanna, Apurv, and William B. White. "The Management Of Hyperkalemia In Patients With Cardiovascular Disease". The American Journal Of Medicine, 2009; 122(3):215-221. Elsevier BV, doi:10.1016/j.amjmed.2008.10.028.
Muzzarelli, Stefano et al. "Frequency And Predictors Of Hyperkalemia In Patients ≥60 Years Of Age With Heart Failure Undergoing Intense Medical Therapy". The American Journal Of Cardiology, 2012; 109(5):693-698. Elsevier BV, doi:10.1016/j.amjcard.2011.10.027.
Palmer, Biff F. "Managing Hyperkalemia Caused By Inhibitors Of The Renin–Angiotensin–Aldosterone System". New England Journal Of Medicine, 2004; 351(6):585-592. Massachusetts Medical Society, doi:10.1056/nejmra035279.
Toto, Robert D. "Serum Potassium And Cardiovascular Outcomes: The Highs And The Lows". Clinical Journal Of The American Society Of Nephrology, 2017; 12(2):221. American Society Of Nephrology (ASN), doi:10.2215/cjn.00030117.
Tromp, Jasper et al. "Serum Potassium Levels And Outcome In Acute Heart Failure (Data From The PROTECT And COACH Trials)". The American Journal Of Cardiology, 2017; 119(2):290-296. Elsevier BV, doi:10.1016/j.amjcard.2016.09.038.
Svensson, Morten et al. "How Prevalent Is Hyperkalemia And Renal Dysfunction During Treatment With Spironolactone In Patients With Congestive Heart Failure?". Journal Of Cardiac Failure, 2004; 10(4):297-303. Elsevier BV, doi:10.1016/j.cardfail.2003.10.012.
Thomsen, Reimar Wernich et al. "Elevated Potassium Levels In Patients With Congestive Heart Failure: Occurrence, Risk Factors, And Clinical Outcomes". Journal of the American Heart Association, 2018; 7(11). Ovid Technologies (Wolters Kluwer Health), doi:10.1161/jaha.118.008912.
Ahuja, Tejinder S. et al. "Predictors Of The Development Of Hyperkalemia In Patients Using Angiotensin-Converting Enzyme Inhibitors". American Journal Of Nephrology, 2000; 20(4):268-272. S. Karger AG, doi:10.1159/000013599.
Ramadan, F. H. et al. "Clinical Factors Associated With Hyperkalemia In Patients With Congestive Heart Failure1". Journal Of Clinical Pharmacy And Therapeutics, 2005; 30(3):233-239. Wiley, doi:10.1111/j.1365-2710.2005.00638.x.
"Cardiovascular Diseases (Cvds)". Who.Int, 2021, https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
Published
Abstract Display: 799 
PDF Downloads: 687 PDF Downloads: 921 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.